Antibiotic resistance is rising at an alarming rate, yet new antimicrobial agents remain scarce. Natural products offer exceptional structural diversity and inherent bioactivity, but their clinical translation is hindered by poor stability, bioavailability, and efficacy. Increasingly, researchers are addressing these limitations by using natural compounds as antibacterial leads, synergistic components, and modifiable scaffolds for structural optimization and advanced delivery. This integrated approach defines the progress highlighted in this Research Topic.

The six contributions in this Research Topic illustrate how natural products continue to serve not only as a source of antimicrobial leads but also as a foundation for subsequent optimization (Table 1; Figure 1). Several studies reaffirmed the intrinsic antibacterial activity of plant- and bee-derived compounds. Murugesan et al. identified 2,4-di-tert-butylphenol from Clidemia hirta as an active agent against Pseudomonas aeruginosa, while Tao et al. demonstrated that carvacrol, a major constituent of oregano essential oil, exhibits broad-spectrum bactericidal activity. Similarly, Martins et al. reported the potent antimycobacterial activity of Brazilian red propolis extract, and Osei Duah et al. identified diverse plant-derived scaffolds as promising candidates for treating ocular tuberculosis. Together, these findings reinforce the continued relevance of natural sources in antimicrobial discovery.

Beyond their inherent antibacterial activity, these studies further highlight the critical role of combination strategies in enhancing antimicrobial efficacy. Tao et al. showed that carvacrol can potentiate tobramycin activity via disruption of bacterial membrane integrity, while Baraich et al. employed a simplex-centroid mixture design to reveal pronounced synergistic interactions among saffron-derived compounds. These observations reflect a broader shift toward leveraging synergistic combinations to amplify antibacterial performance and address resistance.

At the same time, translating natural compounds into clinically viable agents increasingly depends on structural refinement and advanced delivery strategies. Osei Duah et al. emphasized the role of nanocarriers, liposomal systems, and in situ gels in overcoming pharmacokinetic and physiological barriers, particularly in ocular applications. Complementing this, Li et al. developed a pleuromutilin derivative with potent activity against multidrug-resistant Gram-positive bacteria, demonstrating how targeted structural modification can improve efficacy, safety, and resistance profiles.

Taken together, the studies featured in this Research Topic highlight a clear transition from simple activity screening toward more integrated approaches that combine discovery, synergistic optimization, and rational design. These strategies will likely play a central role in advancing natural products from promising bioactive compounds to clinically relevant antimicrobial agents.

Looking ahead, continued progress in this field will rely on close integration across disciplines, including chemistry, microbiology, materials science, and pharmacology. Multidisciplinary collaboration will be essential to fully realize the therapeutic potential of natural products and to develop effective and safe antimicrobial agents capable of addressing the ongoing challenge of drug resistance.